Tag: Biotech and Pharma

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million.

Cardinal Health  reported fourth quarter EPS of $2.60, $0.19 better than the analyst estimate of $2.41. Revenue for the quarter came in at $63.7B versus the consensus estimate of $65.22B.

Shares of Doximity surged more than 80% in premarket trading Friday after the medical networking and telehealth platform missed analysts’ earnings target.

“Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.

There are “no discussions” ongoing between AstraZeneca and ​Bristol Myers Squibb over a potential ‌deal, a senior source close to the matter told Reuters on Wednesday, quashing the ​prospect of a mooted mega merger ​between the drugmakers.

Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro surged again.

Pfizer reported second-quarter revenue of $15.03 billion and raised the midpoint of its full-year revenue guidance on Tuesday.

Merck topped analysts’ second-quarter targets across its top and bottom lines even as dealmaking costs from a recent acquisition weighed on results.

AstraZeneca’s shares fell as investors balked on Monday at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world’s biggest drugmakers with a combined value of nearly $400 billion.

AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.

Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after strong sales of blood thinner Eliquis ​and newer medicines such as heart drug Camzyos and anemia treatment Reblozyl helped ‌second-quarter results top analysts’ estimates.

Drugmaker Johnson & Johnson has announced a $5.5bn agreement to end long-running US litigation involving tens of thousands of claims that talcum powder allegedly caused ovarian cancer.

British pharmaceutical giant AstraZeneca on Monday said net profit rose in the second quarter, driven once again by strong growth in sales of its cancer drugs.

Eli Lilly on Thursday said it will file for approval of its next-generation obesity drug in the first quarter of 2027, as the treatment succeeds in two more late-stage trials. 

Novartis beat ​second-quarter profit forecasts and kept its 2026 expectations unchanged on Tuesday, which analysts said ‌signalled it had shifted some costs into the second half.

Tempus ​AI said ‌on Monday ​it ​would acquire ⁠Personalis ​for about $1.5 ​billion to bringing ​its ​cancer test ‌to ⁠the AI-enabled precision ​medicine ​firm’s ⁠oncology portfolio.

Abbott Laboratories had higher revenue in the second quarter, boosted by more sales in its diagnostics business.

Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion up front, the company said Thursday, as momentum grows for using versions of the drugs as mental health treatments.

UnitedHealth Group on Thursday posted second-quarter earnings that blew past estimates and raised its full-year profit outlook, as the company better manages high medical costs and uses AI to help streamline operations.